Basic and Preclinical Science
Basic and preclinical scientists at Indiana University School of Medicine conduct leading-edge research on the neurobiology and molecular genetics of Alzheimer’s disease to define disease mechanisms, identify therapeutic targets and create molecules for potential drugs.
Researchers span many departments at IU School of Medicine and collaborate in interdisciplinary research teams through the Stark Neurosciences Research Institute.
Immunotherapy is one of the most promising areas of research in Alzheimer’s disease. The IU Precision Health Initiative leads work on how the body’s own immune system may impact the underlying biology associated with cognitive decline, the primary symptom of Alzheimer’s disease. New immune biomarkers, together with existing biomarkers, will help better predict onset and progression of the disease. Researchers work to investigate and develop immune-based therapies that positively impact these biomarkers.